Biosynth, a supplier of critical raw materials and services for diagnostics, vaccines, and pharmaceuticals, is pleased to announce the next step in its custom peptide revolution.
Agios sells vorasidenib US royalties for $905m – Pharmaceutical Technology
Caption: Royalty Pharma projects more than $1bn in annual peak sales for vorasidenib. Image credit: Shutterstock/ ADragan. As Servier’s day of reckoning with US Food